Poviztra will be available in a once-weekly pen device in five strengths—0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg. Prices start at Rs 8,790 per month for four weekly doses, Emcure added.
The pen device is designed to simplify administration and provide precise dosing, the company said.
The medication is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or higher, particularly in the presence of at least one weight-related condition, including hypertension, type 2 diabetes mellitus, or dyslipidemia. Poviztra is also indicated to reduce the risk of major adverse cardiovascular events in adults.
“India is facing a significant obesity crisis, having nearly 254 million people living with generalised obesity and an additional 351 million living with abdominal obesity. The introduction of Poviztra marks an important step in expanding equitable access to scientifically validated weight-management solutions,” Emcure Pharmaceuticals CEO and Managing Director Satish Mehta said.
